Sobi is a global biopharma company transforming the lives of people with rare and debilitating diseases.
Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia.
In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.
NASP and Uncontrolled gout
Sobi hosted an investor conference call on 16 September to discuss the clinical program overview for NASP (previously known as SEL-212) and the uncontrolled gout disease landscape.
Loading...
Press releases
Upcoming events
Loading...